Review Article
Huperzine A in the Treatment of Alzheimer's Disease and Vascular Dementia: A Meta-Analysis
Table 3
Incidence of adverse events for AD.
|
Adverse event | Number of subjects (pooled occurrence) |
Odd ratio (fixed) 95% CI | Huperzine A () | Placebo () |
| Agitation | 3 (0.83) | 3 (0.80) | 1.04 [0.21, 5.17] | Ankles edema | 1 (0.28) | 0 (0.00) | 3.12 [0.13, 76.76] | Anorexia | 12 (3.33) | 6 (1.60) | 2.11 [0.78, 5.68] | Bradycardia | 0 (0.00) | 1 (0.27) | 0.34 [0.01, 8.48] | Constipation | 4 (1.11) | 0 (0.00) | 9.43 [0.51, 175.77] | Diarrhea | 5 (1.39) | 2 (0.54) | 2.61 [0.50, 13.55] | Dizziness | 9 (2.5) | 12 (3.21) | 0.77 [0.32, 1.85] | Dry mouth | 4 (1.11) | 0 (0.00) | 9.43 [0.51, 175.77] | Diaphoresis | 4 (1.11) | 0 (0.00) | 9.43 [0.51, 175.77] | Dimness of vision | 0 (0.00) | 1 (0.27) | 0.34 [0.01, 8.48] | Festinating gait | 0 (0.00) | 1 (0.27) | 0.34 [0.01, 8.48] | Headache | 2 (0.56) | 4 (1.07) | 0.52 [0.09, 2.83] | Hyperactivity | 5 (1.39) | 3 (0.80) | 1.74 [0.41, 7.32] | Hypopraxia | 0 (0.00) | 1 (0.27) | 0.34 [0.01, 8.48] | Hypersomnia | 4 (1.11) | 0 (0.00) | 9.43 [0.51, 175.77] | Indigestion | 5 (1.39) | 2 (0.54) | 2.61 [0.50, 13.55] | Insomnia | 6 (1.67) | 6 (1.60) | 1.04 [0.33, 3.24] | Mild bellyache | 6 (1.67) | 0 (0.00) | 13.70 [0.77, 244.02] | Nasal obstruction | 4 (1.11) | 4 (1.07) | 1.04 [0.26, 4.18] | Nausea or vomiting | 15 (4.16) | 5 (1.34) | 3.20 [1.15, 8.90] |
|
|